论文部分内容阅读
目的:观察吉西他滨联合卡铂在老年晚期非小细胞肺癌(NSCLC)中的疗效和毒性。方法:2005年11月至2007年12月共41例患者入组,中位年龄69(65～75)岁。治疗方案:吉西他滨1100mg/m2d1d8,卡铂(AUC=4)d1,21天为1周期,2周期后采用RECIST标准评价疗效。结果:总有效率:41.5%,初治有效率:50%,复治有效率:31.6%。初治与复治疗效间无统计学差异(P>0.05)。中位生存期:9.1个月,1年生存率:37.5%。结论:吉西他滨联合卡铂治疗老年非小细胞肺癌疗效较好,毒副反应可耐受,值得临床进一步推广。
Objective: To observe the efficacy and toxicity of gemcitabine combined with carboplatin in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods: From November 2005 to December 2007 a total of 41 patients were enrolled, with a median age of 69 (65-75) years. Treatment options: gemcitabine 1100mg / m2d1d8, carboplatin (AUC = 4) d1, 21 days for the 1 cycle, 2 cycles after the use of the RECIST standard evaluation of efficacy. Results: The total effective rate: 41.5%, initial effective rate: 50%, retreatment effective rate: 31.6%. There was no significant difference between the initial treatment and the second treatment (P> 0.05). Median survival: 9.1 months, 1 year survival rate: 37.5%. Conclusion: Gemcitabine combined with carboplatin in the treatment of elderly non-small cell lung cancer has good curative effect and toxic side effects. It is worth further clinical promotion.